Furthermore, we showed that both tumor proliferation and interferon-gamma response scores were significantly higher in the HER2 mutation subgroup than in the HER2 wide-type subgroup in the TCGA Pan-Cancer cohort (Figure 4D). This evidence concerns the gene ERBB2 and cancer.